Lavanya Bellumkonda, MD
Associate Professor of Medicine (Cardiovascular Medicine)Cards
About
Research
Publications
2026
Discordance of Aortic Valve Area Indexed to Actual and Ideal Body Surface Area in Aortic Stenosis
Reinhardt S, Singh J, Shah N, McNamara R, Sugeng L, Agarwal V, Hur D, Lombo B, Bellumkonda L, Akintoye E, Shkolnik E, Velazquez E, Faridi K. Discordance of Aortic Valve Area Indexed to Actual and Ideal Body Surface Area in Aortic Stenosis. Journal Of The American Society Of Echocardiography 2026 PMID: 41997251, DOI: 10.1016/j.echo.2026.03.013.Peer-Reviewed Original Research(150) Correlation Between Donor Derived Cell Free DNA and Cardiac Allograft Vasculopathy Detected by PET Myocardial Perfusion Imaging: Minidepict Study
Feher A, Testani J, Maenza C, Hsueh C, Bellumkonda L. (150) Correlation Between Donor Derived Cell Free DNA and Cardiac Allograft Vasculopathy Detected by PET Myocardial Perfusion Imaging: Minidepict Study. The Journal Of Heart And Lung Transplantation 2026, 45: 72-73. DOI: 10.1016/j.healun.2026.02.156.Peer-Reviewed Original Research26-A-15438-ACC IMPACT OF ECHOCARDIOGRAPHIC RIGHT VENTRICULAR DYSFUNCTION ON OUTCOMES IN PATIENTS WITH CARDIOGENIC SHOCK DUE TO ACUTE MYOCARDIAL INFARCTION UNDERGOING PCI WITH IMPELLA PLVAD SUPPORT: A RECOVER III SUBSTUDY
Bellumkonda L, Goli S, Shah J, Hanson I, Falah B, Thompson J, Schonning M, Grines C, Bharadwaj A, Cohen D, Burkhoff D, Basir M, O'Neill W, Lansky A. 26-A-15438-ACC IMPACT OF ECHOCARDIOGRAPHIC RIGHT VENTRICULAR DYSFUNCTION ON OUTCOMES IN PATIENTS WITH CARDIOGENIC SHOCK DUE TO ACUTE MYOCARDIAL INFARCTION UNDERGOING PCI WITH IMPELLA PLVAD SUPPORT: A RECOVER III SUBSTUDY. Journal Of The American College Of Cardiology 2026, 87: a1138. DOI: 10.1016/j.jacc.2026.02.2792.Peer-Reviewed Original ResearchCoronary calcifications and myocardial flow reserve in heart transplant patients: a longitudinal study
Wright C, Kiage J, Kyriakoulis I, Csecs I, Ahmed A, Tong G, Zeng Y, Liu Y, Bellumkonda L, Kokkinidis D, Sinusas A, Miller E, Feher A. Coronary calcifications and myocardial flow reserve in heart transplant patients: a longitudinal study. European Heart Journal 2026, 47: 3214-3216. PMID: 41780909, DOI: 10.1093/eurheartj/ehag163.Peer-Reviewed Original Research3D echo derived right ventricular principal surface strain in pulmonary arterial hypertension
Oakland H, Bellumkonda L, Sugeng L, Joseph P, Kundu P, Izzi D, Zalik F, McCabe S, Raza A, Amendola R, Heerdt P, Hunter K, Singh I. 3D echo derived right ventricular principal surface strain in pulmonary arterial hypertension. AJP Heart And Circulatory Physiology 2026, 330: h729-h736. PMID: 41616802, PMCID: PMC13097151, DOI: 10.1152/ajpheart.00923.2025.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertension patientsPulmonary arterial hypertensionRV systolic functionRight heart catheterizationSystolic functionEchocardiographic representationArterial hypertensionControl patientsOptimal cutoffRight heartNew York Heart Association functional classRight ventricular (RV) functionTricuspid annular plane systolic excursionAnnular plane systolic excursionFunctional classLongitudinal systolic functionThirty-day outcomesSystolic excursionPAH patientsRV functionHeart catheterizationPrognostic valueThirty-dayHemodynamic criteriaRobust markersThe environmental exposome in heart failure risk and progression
Hahad O, Wass S, Rajagopalan S, Abohashem S, Hao H, Navas-Acien A, Bellumkonda L, Chen K, Brook R, Nasir K, Lurz P, Lanfear D, Bhimaraj A, Al-Kindi S. The environmental exposome in heart failure risk and progression. Nature Reviews Cardiology 2026, 23: 457-472. PMID: 41582253, DOI: 10.1038/s41569-026-01247-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSocial determinantsCardiovascular healthSocial determinants of healthDeterminants of healthReduced riskPublic health interventionsReduced risk of HFHF outcomesRisk of HFWalkable neighborhoodsHealth interventionsMedication adherenceSocioeconomic statusPrevention strategiesVulnerable populationsHeart failure riskHealthEnvironmental exposuresRisk predictionHeart failureVascular healthExposomeGenetic predispositionEarly lifeOutcomesClinical outcomes of aortic stenosis patients undergoing Impella-supported high-risk percutaneous coronary intervention
Velagapudi P, Bellumkonda L, Cohen D, Lansky A, Abu-Much A, Thompson J, Schonning M, Redfors B, Zhou Z, Grines C, Maini A, Li Y, Batchelor W, O’Neill W. Clinical outcomes of aortic stenosis patients undergoing Impella-supported high-risk percutaneous coronary intervention. Frontiers In Cardiovascular Medicine 2026, 12: 1638259. PMID: 41573507, PMCID: PMC12819752, DOI: 10.3389/fcvm.2025.1638259.Peer-Reviewed Original ResearchPercutaneous coronary interventionHigh-risk PCIAortic stenosisHigh-risk percutaneous coronary interventionPCI-related complicationsSevere ASAS severityClinical outcomesMulticenter investigationHigher left ventricular ejection fractionCoronary interventionRisk of adverse outcomesVentricular ejection fractionSevere aortic stenosisAortic stenosis patientsIn-Hospital ComplicationsLeft main diseaseHigh-risk populationIncidence of diabetesIII studiesTransfusion rateEjection fractionEchocardiographic dataNo significant differenceSingle-arm
2025
Air Pollution and Exposomic Impacts on Heart Failure
Bellumkonda L, Khawaja T, Al-Kindi S, Khraishah H, Rajagopalan S. Air Pollution and Exposomic Impacts on Heart Failure. Circulation Heart Failure 2025, 19: e013338. PMID: 41347303, DOI: 10.1161/circheartfailure.125.013338.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAir pollution exposureLong-term air pollution exposurePollution exposureAir pollutionEnvironmental risk factorsSocial exposomeEnvironmental health threatsUnderserved populationsHealthcare systemModifiable driversEpidemiological evidenceHeart failureLife courseAir pollution risksBehavioral exposureRisk factorsClinical frameworkPractice strategiesPollution riskCardiovascular morbidityMitigation interventionsPollutionHealth threatRiskCardiovascular impactLoop Diuretic Dose Intensification versus Adjuvant Thiazide for Diuretic Resistance in Acute Heart Failure
Rao V, Cox Z, Ivey-Miranda J, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Turner J, Wilson F, Shilpak M, Estrella M, Welling P, Wilcox C, Ellison D, Forbush B, Testani J. Loop Diuretic Dose Intensification versus Adjuvant Thiazide for Diuretic Resistance in Acute Heart Failure. Journal Of The American Society Of Nephrology 2025, 37: 533-544. PMID: 40938670, PMCID: PMC12935386, DOI: 10.1681/asn.0000000887.Peer-Reviewed Original ResearchFractional excretion of lithiumDose intensificationDiuretic resistanceDiuretic responseFractional excretionHeart failurePrimary outcomeResistance mechanismsLoop diuretic resistanceAcute heart failureExcretion of lithiumLoop of HenleDiuretic strategyRandomized Controlled TrialsSite of actionPrimary trial outcomeOptimal therapyThiazideScreening visitNatriuresisControlled TrialsPatientsInduced increaseExploratory analysisTherapySCAI/EAPCI/ACVC Expert Consensus Statement on Cardiogenic Shock in Women.
Baron S, Chou J, Shah T, Vest A, Abbott J, Alasnag M, Aurigemma C, Barbato E, Bellumkonda L, Bortnick A, Chieffo A, van Geuns R, Grines C, Halvorsen S, Hassager C, Kapur N, Naidu S, Ng V, Saw J, Lansky A. SCAI/EAPCI/ACVC Expert Consensus Statement on Cardiogenic Shock in Women. EuroIntervention 2025, 21: 894-909. PMID: 40387531, PMCID: PMC12337771, DOI: 10.4244/eij-d-24-01126.Peer-Reviewed Original ResearchWomen's cardiovascular healthCardiogenic shockConsensus statementSex-based disparitiesCardiovascular healthExpert consensus statementCardiovascular disease statesTreatment of CSCardiovascular diseaseTreatment of womenWomenPoor outcomeDisparitiesDisease statesCS treatmentTreatmentPracticeHealthClinicians
Clinical Trials
Current Trials
Ertugliflozin in Acute Heart Failure
IRB ID2000027951RoleSub InvestigatorPrimary Completion Date01/31/2022Recruiting ParticipantsGenderBothAge18+ yearsTranscatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation (APOLLO)
IRB ID2000021883RoleSub InvestigatorPrimary Completion Date10/31/2021Recruiting ParticipantsGenderBothAge18+ years
Academic Achievements & Community Involvement
Clinical Care
Overview
As a cardiologist who specializes in advanced heart failure and transplantation, Lavanya Bellumkonda, MD, says offering hope is key when she first meets a patient.
“When someone hears the term ‘heart failure,’ they may think they are dying imminently. I first review the severity of their disease and try to set realistic expectations. A number of patients with heart failure will have improvement in their cardiac function with appropriate medical therapy,” she explains. “If their disease is advanced, they may need a mechanical pump to assist the heart or a heart transplantation, and we discuss the success rates and risks associated with each of these strategies.”
Heart failure describes any kind of dysfunction in the heart that causes a build-up of fluids, resulting in shortness of breath, fatigue, and swelling in the legs. Dr. Bellumkonda says she was drawn to her field because of her fascination with the physiology of the heart and the acuity of cardiac illnesses.
“What I also like about transplant cardiology is that you get to apply all that you learnt in medicine and cardiology,” she says. “Post-transplant, patients often rely on me to manage their medical conditions as well.”
Additionally, Dr. Bellumkonda treats patients with valve disease. “The most common valves affected are the mitral or aortic valves, where these valves get either too tight or too leaky, causing symptoms similar to heart failure,” she says. “At Yale, we treat these patients in a multidisciplinary fashion and provide appropriate recommendations regarding catheter-based interventions and surgery.”
Her research interests include cardiac recovery and cardio-renal reactions in patients with valve disease. “What makes me most happy in my work is when I have cardiac recovery in my patients, meaning they have an improvement in their heart function,” she says. “That makes me feel like I have done my job.”
Clinical Specialties
Fact Sheets
Ventricular Assist Device (VAD)
Learn More on Yale MedicineCongestive Heart Failure (CHF)
Learn More on Yale MedicineExtracorporeal Membrane Oxygenation (ECMO)
Learn More on Yale MedicineHeart Failure Surgery
Learn More on Yale Medicine
Yale Medicine News
News
News
Get In Touch
Contacts
Cardiovascular Medicine
333 Cedar St., PO Box 20817
New Haven, CT 06520
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.